Hannah den Braanker
Hannah is a rheumatology resident and clinician-scientist at Erasmus MC, Rotterdam, the Netherlands. Her research focuses on the transition from psoriasis to psoriatic arthritis, using flow cytometry, single-cell sequencing, and lymphatic biology to dissect early immunopathogenesis. Her ongoing work also includes an immunometabolic GLP-1RA cohort study in patients with PsA and RA. She is a member of the Dutch Society for Rheumatology (NVR) and GRAPPA. Hannah is a member of the EMEUNET Newsletter sub-committee.
| Late-Breaking Oral Presentation, LB0001 | Saturday, 6th of June 2026, 12:00 BST Late Breaking Abstracts (Oral Presentations) Author: I.B. McInnes (United Kingdom) Title: Bimekizumab efficacy & safety versus risankizumab in patients with active psoriatic arthritis: 16-week results from a head-to-head, multicentre, randomised, phase 3B study (BE BOLD)  The first head-to-head trial of an IL-17A/F inhibitor versus an IL-23 inhibitor in PsA. In 553 patients with active PsA randomised 1:1 to bimekizumab or risankizumab, bimekizumab achieved superior ACR50 at week 16 (49.1% vs 38.4%, p=0.0078), with consistently higher response across most secondary measures. Positions dual IL-17A/F inhibition as a new therapeutic modality in PsA, with results that hint at, but do not yet establish, a mechanistic edge of targeting the effector cytokine over its upstream driver. |
| Oral Presentation, OP0185| Thursday, 4th of June 2026, 09:05-09:15 Basic and Clinical Abstract Sessions: Optimising care in Psoriatic Arthritis (Oral Presentations) Author: L.M. Nielung (Denmark) Title: Treatment retention and clinical remission in 787 real-world patients with psoriatic arthritis treated with bimekizumab: results from 12 registries in the European Spondyloarthritis Research Collaboration Network The largest real-world study of bimekizumab in PsA to date. Across 787 patients from 12 European registries — 86% bio-experienced — six-month drug retention was 76% (61% at twelve months), with 55% achieving DAPSA28 low disease activity at six months, irrespective of the number of prior biologics. Showing Bimekizumab as an real-world option in heavily pretreated patients who often fall outside RCT eligibility windows. |
| Poster, POS0472| Wednesday, 3rd of June 2026, 15:30-16:30 Poster View I, K208 Author: S. Lembke (Germany) Title: Treatment inefficacy in psoriatic arthritis: do the new EULAR and GRAPPA definitions identify the same patients? Data from the RABBIT-SpA register How do the new EULAR (D2M) and GRAPPA (C2M) definitions of inadequately-responding patients with PsA compare? Applied to 1,009 patients in the RABBIT-SpA registry, EULAR D2M captured 12% versus GRAPPA C2M 43%, all EULAR D2M were embedded in the GRAPPA C2M. EULAR TR identifies 9% vs GRAPPA TR 4%. Choose your definition with intent — GRAPPA C2M for the broader management challenge, EULAR D2M for the harder-to-treat core. |
| Oral Presentation, OP082| Wednesday, 3rd of June, 2026, 17:20-17:30 Clinical Abstract Sessions: Advanced therapies across rheumatic diseases (Oral Presentations) Author: G.R. Burmester (Germany) Title: Long-term safety of upadacitinib in clinical trial and clinical practice settings: risk of infection, malignancy, cardiovascular events, and thromboembolism in patients with rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis Integrated long-term safety of upadacitinib across RA, PsA and axSpA — 4,998 patients, 17,281 patient-years across the SELECT programme plus five real-world studies. Herpes zoster and non-malignant skin cancer remained elevated versus active comparators in RA and PsA, with PsA serious infections driven mainly by COVID-19. MACE, VTE and overall malignancy were neutral. Crucially, real-world incidence rates aligned with earlier clinical-trial estimates. |
| Poster, POS1350| Saturday, 6th of June, 2026, 10:15-11:15 Poster View VIII, L220 Author: A. Deodhar (USA) Title: Clinical outcomes following withdrawal of upadacitinib in patients with axial spondyloarthritis who achieved remission: findings from the phase 3, placebo-controlled, double-blind SELECT-AXIS 2 trial The first phase 3 placebo-controlled data on JAK-inhibitor withdrawal in axSpA. In 194 patients in deep remission at week 104 of SELECT-AXIS 2, only 22% maintained remission off treatment at 48 weeks (median time to flare 3.1 months). After re-initiation of upadacitinib, 89% achieved ASDAS low disease activity within 24 weeks. A clear numerical anchor for shared decision-making on treatment holidays. |